288 related articles for article (PubMed ID: 10397748)
1. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Larson RA; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau MM; Smith MT
Blood; 1999 Jul; 94(2):803-7. PubMed ID: 10397748
[TBL] [Abstract][Full Text] [Related]
2. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children.
Smith MT; Wang Y; Skibola CF; Slater DJ; Lo Nigro L; Nowell PC; Lange BJ; Felix CA
Blood; 2002 Dec; 100(13):4590-3. PubMed ID: 12393620
[TBL] [Abstract][Full Text] [Related]
3. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.
Sirma S; Agaoglu L; Yildiz I; Cayli D; Horgusluoglu E; Anak S; Yuksel L; Unuvar A; Celkan T; Apak H; Karakas Z; Devecioglu O; Ozbek U
Pediatr Blood Cancer; 2004 Oct; 43(5):568-70. PubMed ID: 15382274
[TBL] [Abstract][Full Text] [Related]
5. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
[TBL] [Abstract][Full Text] [Related]
6. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS.
Fern L; Pallis M; Ian Carter G; Seedhouse C; Russell N; Byrne J
Br J Haematol; 2004 Jul; 126(1):63-71. PubMed ID: 15198733
[TBL] [Abstract][Full Text] [Related]
7. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
8. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.
Bolufer P; Collado M; Barragan E; Calasanz MJ; Colomer D; Tormo M; González M; Brunet S; Batlle M; Cervera J; Sanz MA
Br J Haematol; 2007 Feb; 136(4):590-6. PubMed ID: 17367411
[TBL] [Abstract][Full Text] [Related]
9. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults.
Smith MT; Wang Y; Kane E; Rollinson S; Wiemels JL; Roman E; Roddam P; Cartwright R; Morgan G
Blood; 2001 Mar; 97(5):1422-6. PubMed ID: 11222389
[TBL] [Abstract][Full Text] [Related]
10. The frequencies of NAD(P)H quinone oxidoreductase (NQO1) variant allele in Israeli ethnic groups and the relationship of NQO1*2 to adult acute myeloid leukemia in Israeli patients.
Malik E; Cohen SB; Sahar D; Dann EJ; Rund D
Haematologica; 2006 Jul; 91(7):956-9. PubMed ID: 16818284
[TBL] [Abstract][Full Text] [Related]
11. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Dissing M; Le Beau MM; Pedersen-Bjergaard J
J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
[TBL] [Abstract][Full Text] [Related]
12. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
Blanco JG; Edick MJ; Hancock ML; Winick NJ; Dervieux T; Amylon MD; Bash RO; Behm FG; Camitta BM; Pui CH; Raimondi SC; Relling MV
Pharmacogenetics; 2002 Nov; 12(8):605-11. PubMed ID: 12439220
[TBL] [Abstract][Full Text] [Related]
14. High frequency of NAD(P)H:quinone oxidoreductase 1 (NQO1) C(609)T germline polymorphism in MDS/AML with trisomy 8.
Zachaki S; Stavropoulou C; Koromila T; Manola KN; Kalomoiraki M; Daraki A; Koumbi D; Athanasiadou A; Kanavakis E; Kollia P; Sambani C
Leuk Res; 2013 Jul; 37(7):742-6. PubMed ID: 23643325
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
[TBL] [Abstract][Full Text] [Related]
16. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
Super HJ; McCabe NR; Thirman MJ; Larson RA; Le Beau MM; Pedersen-Bjergaard J; Philip P; Diaz MO; Rowley JD
Blood; 1993 Dec; 82(12):3705-11. PubMed ID: 8260707
[TBL] [Abstract][Full Text] [Related]
17. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
[TBL] [Abstract][Full Text] [Related]
18. Incidence and susceptibility to therapy-related myeloid neoplasms.
Leone G; Fianchi L; Pagano L; Voso MT
Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review.
Nebert DW; Roe AL; Vandale SE; Bingham E; Oakley GG
Genet Med; 2002; 4(2):62-70. PubMed ID: 11882782
[TBL] [Abstract][Full Text] [Related]
20. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
Lezon-Geyda K; Najfeld V; Johnson EM
Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
